Clinical trial NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion
NCT07063745 — is «recruiting» on ClinicalTrials.gov.
Clinical trial NCT07063745 (phase II/III) is «recruiting» on ClinicalTrials.gov.
Condition: Metastatic Non-small Cell Lung Cancer With MTAP Deletion · Registered interventions: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel · Recorded dates (source): 2026-01-02, 2031-08-12, 2025-07-14, 2026-10-23.
Study summary (source: ClinicalTrials.gov):
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion